Prevalence of Lung Fibrosis in Post-COVID Patients
DOI:
https://doi.org/10.54112/bcsrj.v6i3.2155Keywords:
COVID-19, Pulmonary Fibrosis, High-Resolution CT, Post-COVID Complications, Long-Term OutcomesAbstract
Progressive fibrotic lung disease is one of the possible consequences of COVID-19 pulmonary pneumonia, and it is one of the most worrying long-term complications. Objective: The main aim of the study is to determine the prevalence of lung fibrosis in post-COVID-19 patients. Methods: This Cross-sectional study was conducted at the Department of Medicine, PAF Hospital, Mushaf, Sargodha, from June 2024 to November 2024. Data were collected using a nonprobability consecutive sampling technique. A detailed history and physical examination were conducted for all eligible patients. High-resolution chest CT scans were performed in the supine position at full inspiration, with the patient in a foot-first position. Results: A total of 150 patients were added, with a mean age of 51.3 ± 12.6 years (range: 25–75 years). Of the participants, 60% (n = 90) were male, and 40% (n = 60) were female. A significant proportion (68%, n = 102) reported a history of moderate-to-severe COVID-19 illness during their initial infection. Pulmonary fibrosis was prevalent in 41.3% (n = 62) of the total study population. Among fibrosis-positive patients, 65% (n = 40) were male, and 35% (n = 22) were female, indicating a higher proportion of males. The prevalence was significantly higher in patients aged ≥50 years (53%, n = 45) than in those aged <50 years (22%, n = 17). Conclusion: It is concluded that pulmonary fibrosis is a significant complication in post-COVID-19 patients, particularly in older individuals. Regular follow-up and early diagnosis are recommended for at-risk populations. Further research is needed to explore therapeutic interventions and the long-term progression of fibrosis.
Downloads
References
Ali RMM, Ghonimy MBI. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egypt J Radiol Nucl Med. 2021;52(1):101. https://doi.org/10.1186/s43055-021-00484-3
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Li X, Shen C, Wang L, Majumder S, Zhang D, Deen MJ, et al. Pulmonary fibrosis and its related factors in discharged patients with new coronavirus pneumonia: a cohort study. Respir Res. 2021;22(1):203. https://doi.org/10.1186/s12931-021-01798-6
Mohammadi A, Balan I, Yadav S, Matos WF, Kharawala A, Gaddam M, et al. Post-COVID-19 pulmonary fibrosis. Cureus. 2022;14(3):e22770. https://doi.org/10.7759/cureus.22770
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433
Sgalla G, Comes A, Lerede M, Richeldi L. COVID-related fibrosis: insights into potential drug targets. Expert Opin Investig Drugs. 2021;30(12):1183-1195. https://doi.org/10.1080/13543784.2021.2010188
Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after COVID-19: treatment prospects. Pharmaceuticals (Basel). 2021;14(8):807. https://doi.org/10.3390/ph14080807
King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017;5(1):72-84. https://doi.org/10.1016/S2213-2600(16)30222-3
Udwadia ZF, Pokhariyal PK, Tripathi AKR, Kohli A. Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India. 2021;38(Suppl 1):S61-S63. https://doi.org/10.4103/lungindia.lungindia_533_20
Alrajhi NN. Post-COVID-19 pulmonary fibrosis: an ongoing concern. Ann Thorac Med. 2023;18(4):173-181. https://doi.org/10.4103/atm.atm_7_23
Zheng Z, Peng F, Zhou Y. Pulmonary fibrosis: a short- or long-term sequelae of severe COVID-19? Chin Med J Pulm Crit Care Med. 2023;1(2):77-83. https://doi.org/10.1016/j.pccm.2022.12.002
Nie X, Qian L, Sun R, et al. Multi-organ proteomic landscape of COVID-19 autopsies. Cell. 2021;184(3):775-791.e14. https://doi.org/10.1016/j.cell.2021.01.004
Mylvaganam RJ, Bailey JI, Sznajder JI, Sala MA; Northwestern Comprehensive COVID Center Consortium. Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev. 2021;30(162):210194. https://doi.org/10.1183/16000617.0194-2021
Banerjee AK, Blanco MR, Bruce EA, et al. SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell. 2020;183(5):1325-1339.e21. https://doi.org/10.1016/j.cell.2020.10.004
Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q, Huynh-Anh T, Vo-Van T, Vu-Tran-Thien Q, Nguyen-Nhu V. Post-COVID-19 pulmonary fibrosis: facts, challenges, and futures: a narrative review. Pulm Ther. 2023;9(3):295-307. https://doi.org/10.1007/s41030-023-00226-y
Yu D, Yin G, Lei J, Gong Y, Zheng L, He D, Lei L, Sun L. The correlation between serum levels of laminin, type IV collagen, type III procollagen N-terminal peptide, and hyaluronic acid with the progression of post-COVID-19 pulmonary fibrosis. Front Cell Dev Biol. 2024;12:1382244. https://doi.org/10.3389/fcell.2024.1382244
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mahnoor Asghar, Ayaz Ahmed, Aamir Hussain, Muhammad Omer, Mehmood Hussain, Sumia Jabeen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
